Atara Biotherapeutics Inc
ATRA
查看详细走势图
17.170USD
-0.060-0.35%
收盘 12/19, 16:00（美东）报价延迟15分钟
123.80M总市值
5.94市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.35%
5天
-4.58%
1月
+25.51%
6月
+116.25%
今年开始到现在
+29.00%
1年
+50.61%
查看详细走势图
TradingKey Atara Biotherapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Atara Biotherapeutics Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名130/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价17.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Atara Biotherapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
17.000
目标均价
+12.73%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Atara Biotherapeutics Inc亮点
亮点风险
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
业绩高增长
公司营业收入稳步增长，连续3年增长102.82%
估值高估
公司最新PE估值5.93，处于3年历史高位
机构加仓
最新机构持股3.30M股，环比增加0.09%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值18.94K
Atara Biotherapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Atara Biotherapeutics Inc简介
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
公司代码ATRA
公司Atara Biotherapeutics Inc
CEONguyen (Anhco)
网址https://www.atarabio.com/
常见问题
Atara Biotherapeutics Inc(ATRA)的当前股价是多少？
Atara Biotherapeutics Inc(ATRA)的当前股价是 17.170。
Atara Biotherapeutics Inc的股票代码是什么？
Atara Biotherapeutics Inc的股票代码是ATRA。
Atara Biotherapeutics Inc股票的52周最高点是多少？
Atara Biotherapeutics Inc股票的52周最高点是18.705。
Atara Biotherapeutics Inc股票的52周最低点是多少？
Atara Biotherapeutics Inc股票的52周最低点是5.005。
Atara Biotherapeutics Inc的市值是多少？
Atara Biotherapeutics Inc的市值是123.80M。
Atara Biotherapeutics Inc的净利润是多少？
Atara Biotherapeutics Inc的净利润为-85.40M。
现在Atara Biotherapeutics Inc(ATRA)的股票是买入、持有还是卖出？
根据分析师评级，Atara Biotherapeutics Inc(ATRA)的总体评级为买入，目标价格为17.000。
Atara Biotherapeutics Inc(ATRA)股票的每股收益（EPS TTM）是多少
Atara Biotherapeutics Inc(ATRA)股票的每股收益（EPS TTM）是2.893。
相关品种
